Lite Strategy: the first public company betting its treasury on Litecoin

From cancer drugs to crypto: the MEI Pharma pivot

In August 2025, MEI Pharma — a Nasdaq-listed pharmaceutical company with a market cap under $50 million and a pipeline of cancer drug candidates going nowhere — announced it was buying 929,548 Litecoin for approximately $100 million. The average purchase price was $107.58 per LTC. The company then rebranded to Lite Strategy, changed its Nasdaq ticker from MEIP to LITS, and appointed Charlie Lee (Litecoin's creator) and Joshua Riezman (GSR's U.S. Chief Strategy Officer) to its board.

This is not subtle. A publicly traded pharmaceutical company abandoned drug development to become the first LTC treasury company on a US national exchange. Whether this is visionary or reckless depends entirely on what LTC does from here — and as of March 2026, the trade is deeply underwater.

The numbers: $100M in, now worth ~$50M

At $54 per LTC, Lite Strategy's holdings are worth roughly half what they paid. That 929,548 LTC represents approximately 1.24% of all mined Litecoin — a concentration that makes LITS the single largest known LTC holder outside of exchanges. Track large holder movements on our whale tracker.

How the acquisition worked

MEI Pharma funded the purchase through a $100 million private placement — selling 29,239,767 shares at $3.42 each to institutional investors. This diluted existing shareholders significantly but gave the company a war chest to execute the LTC buy. GSR, one of the largest crypto market makers and OTC desks, advised on the acquisition and likely executed the trades.

Key structural details:

• Private placement, not open market: buying 929,548 LTC on exchanges would have moved the price dramatically. At ~$400M daily LTC volume, a $100M buy executed over days would have created a 5-10% price spike from slippage alone. OTC execution through GSR avoided this
• Charlie Lee on the board: having Litecoin's creator as a board member gives LITS direct access to Foundation roadmap decisions and ecosystem intelligence. It also creates a potential conflict of interest — Lee has been transparent about his LTC holdings (he famously sold all his LTC near the 2017 top), but his role at LITS creates new incentive alignment
• $25M share buyback announced October 2025: LITS moved from pure accumulation to capital management, signaling they view the stock as undervalued at current LTC prices

What this means for LTC markets

929,548 LTC sitting in corporate treasury has structural implications:

• Reduced circulating supply: those coins are not being traded, sold for expenses, or moving to exchanges. They are in cold storage. With ~75M LTC mined and an estimated 30-40% actively traded, removing 929K LTC tightens the effective float by 2-3%
• Price floor psychology: knowing a public company holds 1% of supply at a $107 cost basis creates a psychological anchor. If LTC approaches $107, the market knows LITS's P&L turns green — which can attract momentum traders
• Dilution risk at low prices: if LTC stays below $60 for an extended period, LITS may need to raise more capital (diluting shares again) or sell LTC to fund operations. The company still has pharmaceutical R&D expenses for voruciclib and zandelisib, even if development is on pause
• Precedent for corporate adoption: if LITS succeeds (stock price recovers, LTC price rises), other small-cap public companies may copy the treasury model. If LITS fails, it becomes a cautionary tale that discourages corporate crypto adoption for years

The pharmaceutical question

LITS has not fully abandoned pharma. They still hold rights to voruciclib (CDK9 inhibitor) and zandelisib (PI3K-delta inhibitor). The Q1 FY2026 report mentions plans for "preclinical strategy to identify new development opportunities." But make no mistake: this is a crypto treasury company that happens to own some drug candidates, not a pharma company that happens to hold crypto.

The risk: if LTC's price does not recover, LITS's stock may trade below its LTC holdings' net asset value — creating a discount-to-NAV situation similar to Grayscale's LTCN trust. Arbitrage traders would buy the stock and short LTC to capture the spread, but this only works if the discount eventually closes.

What to watch

• Quarterly reports: LITS must mark LTC holdings to market in SEC filings. Each quarterly report reveals exact holdings, cost basis, and unrealized gains/losses
• Additional purchases: if LITS buys more LTC at current prices (~$54), they dollar-cost average their position and signal conviction. Watch for 8-K filings on SEC EDGAR
• Share buyback execution: the $25M buyback program signals management believes the stock is undervalued. Track buyback activity in 10-Q filings
• LTC price vs $107.58: this is LITS's break-even. Below it, the treasury strategy is a loss. Above it, the stock becomes a leveraged bet on LTC. Check current LTC prices on our dashboard
• Copycats: if other public companies announce LTC treasury strategies, it validates LITS's thesis and creates additional structural demand. Monitor corporate announcements

Frequently asked questions

What is Lite Strategy (LITS)?

Lite Strategy (Nasdaq: LITS), formerly MEI Pharma, is the first publicly traded US company to adopt Litecoin as its primary treasury reserve asset. The company holds 929,548 LTC acquired for approximately $100 million at an average price of $107.58.

How much LTC does Lite Strategy hold?

929,548 LTC, representing approximately 1.24% of all mined Litecoin supply. At current prices (~$54), the holding is worth approximately $50 million — roughly half the $100 million cost basis.

Is Lite Strategy profitable?

As of March 2026, Lite Strategy's LTC holdings have an unrealized loss of approximately $50 million. The break-even price is $107.58 per LTC. The company reported $12.21 million in working capital with no debt as of September 30, 2025.

Sources

• MEI Pharma / Lite Strategy — SEC filings and press releases (investor.meipharma.com)
• Nasdaq — LITS ticker transition announcement, September 11, 2025
• BusinessWire — private placement closing announcement
• CoinDesk — Lite Strategy Q1 FY2026 results, November 17, 2025